253 related articles for article (PubMed ID: 34613571)
1. Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma.
Schnoell J; Stanisz I; Jank BJ; Stanek V; Schmid R; Brunner M; Heiduschka G; Kotowski U
Invest New Drugs; 2022 Apr; 40(2):224-231. PubMed ID: 34613571
[TBL] [Abstract][Full Text] [Related]
2. The radiosensitizing effect of β-Thujaplicin, a tropolone derivative inducing S-phase cell cycle arrest, in head and neck squamous cell carcinoma-derived cell lines.
Haas M; Lenz T; Kadletz-Wanke L; Heiduschka G; Jank BJ
Invest New Drugs; 2022 Aug; 40(4):700-708. PubMed ID: 35412173
[TBL] [Abstract][Full Text] [Related]
3. HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines.
Foki E; Stanisz I; Kadletz L; Kotowski U; Seemann R; Schmid R; Heiduschka G
Wien Klin Wochenschr; 2021 Jan; 133(1-2):26-31. PubMed ID: 32876741
[TBL] [Abstract][Full Text] [Related]
4. The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines.
Schnoell J; Sparr C; Al-Gboore S; Haas M; Brkic FF; Kadletz-Wanke L; Heiduschka G; Jank BJ
Invest New Drugs; 2023 Dec; 41(6):842-850. PubMed ID: 37934325
[TBL] [Abstract][Full Text] [Related]
5. Radiosensitizing effect of galunisertib, a TGF-ß receptor I inhibitor, on head and neck squamous cell carcinoma in vitro.
Jank BJ; Lenz T; Haas M; Kadletz-Wanke L; Campion NJ; Schnoell J; Heiduschka G; Macfelda K
Invest New Drugs; 2022 Jun; 40(3):478-486. PubMed ID: 34985593
[TBL] [Abstract][Full Text] [Related]
6. Effect of the histone deacetylase inhibitor resminostat on head and neck squamous cell carcinoma cell lines.
Enzenhofer E; Kadletz L; Stanisz I; Kotowski U; Seemann R; Schmid R; Thurnher D; Heiduschka G
Head Neck; 2017 May; 39(5):900-907. PubMed ID: 28170128
[TBL] [Abstract][Full Text] [Related]
7. Cell Death Induced by the Combination of
Woo SR; Noh JK; Ahn SY; Lee MK; Yu HS; Min S; Kong M; Lee JW; Lee YC; Ko SG; Eun YG
Anticancer Agents Med Chem; 2024; 24(1):50-57. PubMed ID: 37921146
[TBL] [Abstract][Full Text] [Related]
8. Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma.
Ekshyyan O; Rong Y; Rong X; Pattani KM; Abreo F; Caldito G; Chang JK; Ampil F; Glass J; Nathan CO
Mol Cancer Ther; 2009 Aug; 8(8):2255-65. PubMed ID: 19625495
[TBL] [Abstract][Full Text] [Related]
9. HIV Protease Inhibitors Sensitize Human Head and Neck Squamous Carcinoma Cells to Radiation by Activating Endoplasmic Reticulum Stress.
Liu R; Zhang L; Yang J; Zhang X; Mikkelsen R; Song S; Zhou H
PLoS One; 2015; 10(5):e0125928. PubMed ID: 25933118
[TBL] [Abstract][Full Text] [Related]
10. The effect of cilengitide in combination with irradiation and chemotherapy in head and neck squamous cell carcinoma cell lines.
Heiduschka G; Lill C; Schneider S; Seemann R; Kornek G; Schmid R; Kotowski U; Thurnher D
Strahlenther Onkol; 2014 May; 190(5):472-9. PubMed ID: 24557056
[TBL] [Abstract][Full Text] [Related]
11. CDK4/6 Inhibitor LEE011 Is a Potential Radiation-sensitizer in Head and Neck Squamous Cell Carcinoma: An
Tai TS; Lin PM; Wu CF; Hung SK; Huang CI; Wang CC; Su YC
Anticancer Res; 2019 Feb; 39(2):713-720. PubMed ID: 30711949
[TBL] [Abstract][Full Text] [Related]
12. Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells.
Möckelmann N; Rieckmann T; Busch CJ; Becker B; Gleißner L; Hoffer K; Omniczynski M; Steinmeister L; Laban S; Grénman R; Petersen C; Rothkamm K; Dikomey E; Knecht R; Kriegs M
Oncotarget; 2016 Apr; 7(17):23542-51. PubMed ID: 27015558
[TBL] [Abstract][Full Text] [Related]
13. Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer.
Zerp SF; Stoter TR; Hoebers FJ; van den Brekel MW; Dubbelman R; Kuipers GK; Lafleur MV; Slotman BJ; Verheij M
Radiat Oncol; 2015 Jul; 10():158. PubMed ID: 26223311
[TBL] [Abstract][Full Text] [Related]
14. Radiation induced a supra-additive cytotoxic effect in head and neck carcinoma cell lines when combined with plant extracts from Brazilian Cerrado biome.
Elias ST; Borges GA; Amorim DA; Rêgo DF; Simeoni LA; Silveira D; Fonseca-Bazzo YM; Paula JE; Fagg CW; Barros IM; Abreu WC; Pinto-Júnior DS; Magalhães PO; Neves FA; Lofrano-Porto A; Guerra EN
Clin Oral Investig; 2015 Apr; 19(3):637-46. PubMed ID: 25096669
[TBL] [Abstract][Full Text] [Related]
15. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.
Sano D; Matsumoto F; Valdecanas DR; Zhao M; Molkentine DP; Takahashi Y; Hanna EY; Papadimitrakopoulou V; Heymach J; Milas L; Myers JN
Clin Cancer Res; 2011 Apr; 17(7):1815-27. PubMed ID: 21350000
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of BH3 mimetics as a combination therapy with irradiation in head and neck squamous cell carcinoma.
Korelin K; Oostveen M; Wahbi W; Ianevski F; Cavalcante B; Turunen L; Belevich I; Al-Samadi A; Salo T
Biomed Pharmacother; 2024 Jun; 175():116719. PubMed ID: 38749173
[TBL] [Abstract][Full Text] [Related]
17. Radiosensitization of head and neck cancer cells by the phytochemical agent sulforaphane.
Kotowski U; Heiduschka G; Brunner M; Czembirek C; Eder-Czembirek C; Schmidt R; Fahim T; Thurnher D
Strahlenther Onkol; 2011 Sep; 187(9):575-80. PubMed ID: 21858418
[TBL] [Abstract][Full Text] [Related]
18. The antitumor drug F14512 enhances cisplatin and ionizing radiation effects in head and neck squamous carcinoma cell lines.
Mouawad F; Gros A; Rysman B; Bal-Mahieu C; Bertheau C; Horn S; Sarrazin T; Lartigau E; Chevalier D; Bailly C; Lansiaux A; Meignan S
Oral Oncol; 2014 Feb; 50(2):113-9. PubMed ID: 24290982
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a Radiosensitizer for Head and Neck Squamous Cell Carcinoma.
Odhiambo DA; Pittman AN; Rickard AG; Castillo RJ; Bassil AM; Chen J; Ravotti ML; Xu ES; Himes JE; Daniel AR; Watts TL; Williams NT; Luo L; Kirsch DG; Mowery YM
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1315-1327. PubMed ID: 38104870
[TBL] [Abstract][Full Text] [Related]
20. AZD5582, an IAP antagonist that leads to apoptosis in head and neck squamous cell carcinoma cell lines and is eligible for combination with irradiation.
Kadletz L; Enzenhofer E; Kotowski U; Altorjai G; Heiduschka G
Acta Otolaryngol; 2017 Mar; 137(3):320-325. PubMed ID: 27739348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
